Cornea

Building on cyclosporine for dry eyeA phase II study investigating a novel topical cyclosporine product (CyclASol, Novaliq) formulated in a semifluorinated alkane (SFA) vehicle showed promising efficacy, safety, and tolerability. Planning is ongoing for the phase III trial of cyclosporine in the SFA technology.
Novel therapies abound in pipelineThe importance of novel therapies for ocular disease is a given. However, as most novel therapies are financed by the private sector, it is fortunate that investors find ophthalmology a worthwhile investment.
KeraLink poised for new era in corneal transplantationAs part of a transformation to one of the pioneering eye banks in the country, Tissue Banks International (TBI) recently underwent a formal rebranding, changing its name to Kera­Link International. This move included shedding the musculoskeletal portion of operations to concentrate on dramatically increasing the number of sight-saving procedures performed globally, explained Douglas Furlong, Kera­Link’s president and chief executive officer.
Rituximab appears to cure Mooren’s ulcers in 5 patientsMooren’s ulcers completely healed in 5 patients treated with rituximab after conventional treatment failed, according to researchers.
Inlays provide option for presbyopic correctionThree corneal inlays are in clinical use for improving near vision in phakic presbyopic patients with low refractive spherical equivalent.
Is DSAEK still the gold standard over DMEK for endothelial disease?Multiple advantages of DSAEK include successful outcomes, less risk of graft tears, and alternative options for complex patients with comorbidities. Overall, the procedure offers an aspect of simplicity in that it also has less restrictions for donor age criteria compared with DMEK.
Glycoprotein and peptide eyedrops promote healing of epithelial defectsGlycoprotein and peptide eyedrops are effective therapies for non-healing corneal epithelial defects that address underlying causes in the pathophysiology of these lesions.
DSEK or DMEK? Choosing the best for patients with corneal edemaCareful consideration must be given to the timing and choice of surgery in eyes with corneal edema.
Managing treatment options for atopic keratoconjunctivitisEye or eyelid involvement in atopic dermatitis is relatively uncommon. However, the frequency and severity of corneal complications may accompany atopic keratoconjunctivitis and lead to vision loss. In all but the mildest cases of AKC, treatment typically consists of corticosteroids; calcineurin inhibitors may be added in more severe cases.
Risk review supports safety of corneal crosslinkingSevere complications are rare (< 1%) after corneal crosslinking for progressive keratoconus. Some are preventable, some are manageable, but some may lead to a need for corneal transplantation